Startups
Edit
https://www.radiopharmtheranostics.com/
RadioPharm Theranostics
TrustedLast activity: 04.11.2026
Active
Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.
Overview
Location
United States
Employees
1-10
Founded date
2021
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 24, 2026 | AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01) | HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in... |
| Oct 16, 2024 | AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors | HAMILTON, ON, Oct. 16, 2024 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with Radiopharm Ventures (RV), a Joint... |
| Oct 19, 2022 | PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL | F-18 Pivalate PET shows high uptake regardless of origin of primary tumour F-18 Pivalate can be used to monitor cerebral metastases Patients without previous external beam radiation show higher tumour uptake, while those previously treated ... |
| Sep 14, 2022 | MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS | MELBOURNE, Australia, Sept. 14, 2022 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center ('MD Anderson') and Radiopharm Theranostics Limited ('Radiopharm')(ASX: RAD) today announced the launch of Radiopharm... |
| Aug 4, 2022 | RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB | Radiopharm will shortly initiate a PD-L1 Phase 1 therapeutic study in Australia in patients with NSCLC Radiopharm acquired from NanoMab, Ltd. worldwide rights to PD-L1 technology for therapeutic use, as well as to imaging rights in China ME... |
| Jun 10, 2022 | RAD adds brain tumor technology to portfolio | Sublicensing of promising imaging & therapeutic radiopharmaceutical from leading US university, Case Western Reserve University (CWRU), Ohio PTPµ (PTPmu), the target, is a unique biomarker present only in tumor cells but not healthy cel... |
Reviews 0
FAQ about RadioPharm Theranostics
When was RadioPharm Theranostics founded?
RadioPharm Theranostics was founded in 2021.
What has the press written about RadioPharm Theranostics?
Parsers VC has collected 7 articles mentioning RadioPharm Theranostics, among them “AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)” (Feb 24, 2026) and “AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors” (Oct 16, 2024).
Is RadioPharm Theranostics still active?
Yes, RadioPharm Theranostics is active; its latest activity on Parsers VC dates from Nov 4, 2026.